FASTRACK II : A Mulicentre Phase II clinical trial of STereotactic Ablative Body Radiotherapy for Primary Kidney Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18+Age Over 18

Kidney<br/>CancersCancer LocationKidney
Cancers

Radiotherapy | Urinary systemKidney

Trial Overview Read MoreRead more

This phase II trial is trying to determine the effectiveness of using focal ablative stereotactic radiosurgery (targeted radiotherapy) for the treatment of primary kidney cancer.
 

This trial is treating patients with primary kidney cancer.

This is a radiotherapy trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Mulicentre Phase II clinical trial of STereotactic Ablative Body Radiotherapy for Primary Kidney Cancer

Cooperative Group

Trans Tasman Radiation Oncology Group (TROG)

Summary

Definitive external beam radiotherapy (EBRT) is often used to treat medically inoperable patients with cancers in many different organs, including the kidneys. However, renal cell carcinoma (RCC) is conventionally considered “radioresistant” to fully fractionated EBRT. In an effort to overcome the perceived “radioresistance” of RCC, severely hypofractionated EBRT in the form of stereotactic radiotherapy has renewed interest in the management of renal cell carcinoma with radiotherapy. Participants in this study will be allocated to receive either multi-fraction SABR (3 fractions over 2 weeks) or single fraction SABR (1 fraction only). All participants will be assessed at regular intervals post treatment in order to estimate the activity and efficacy of the technique, evaluate tolerability, estimate survival, estimate distant failure rate, and renal function change after SABR. The follow-up visits occur at 4 weeks and every 3 months in the 1st year post treatment, then every 6 months in the second year and then yearly until study closure (2 years after the last participant finishes study treatment).

Recruiting Hospitals Read MoreRead more

Alfred Hospital, William Buckland Radiotherapy Centre
Prahran
Ms Robin Smith
robin.smith@wbrc.org.au
03 9076 2360

Peter MacCallum Cancer Centre, Radiation Oncology
Parkville
Ms Jenny Trinh
Jenny.Trinh@petermac.org
03 8559 8482

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next